Fuho Pharmaceutical (02696): The European Commission (EC) has approved two new indications for the injection of Surlitinib.

Intelligent Financial App News, Fosun Pharma (02696) announced that the European Commission (EC) has recently approved two new indications for the company's self-developed injection of serplulimab (trade name in China: Hanshuang; trade name in EU: HETRONIFLY). The approved indications are: (1) Serplulimab in combination with fluoropyrimidine and platinum-based chemotherapy is indicated for first-line treatment of PD-L1 positive adult patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with a combined positive score (CPS)5; and (2) Serplulimab in combination with carboplatin and pemetrexed is indicated for first-line treatment of adult patients with unresectable locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC) who are negative for EGFR gene mutations, ALK or ROS1. This approval means that the two new indications for serplulimab have been approved in all EU member states, as well as Iceland, Liechtenstein, and Norway (each being a European Economic Area (EEA) country).